296 related articles for article (PubMed ID: 10844038)
21. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.
Choi-Lundberg DL; Lin Q; Schallert T; Crippens D; Davidson BL; Chang YN; Chiang YL; Qian J; Bardwaj L; Bohn MC
Exp Neurol; 1998 Dec; 154(2):261-75. PubMed ID: 9878166
[TBL] [Abstract][Full Text] [Related]
22. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
[TBL] [Abstract][Full Text] [Related]
23. Long-term restoration of nigrostriatal system function by implanting GDNF genetically modified fibroblasts in a rat model of Parkinson's disease.
Duan D; Yang H; Zhang J; Zhang J; Xu Q
Exp Brain Res; 2005 Mar; 161(3):316-24. PubMed ID: 15480595
[TBL] [Abstract][Full Text] [Related]
24. In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artemin.
Rosenblad C; Grønborg M; Hansen C; Blom N; Meyer M; Johansen J; Dagø L; Kirik D; Patel UA; Lundberg C; Trono D; Björklund A; Johansen TE
Mol Cell Neurosci; 2000 Feb; 15(2):199-214. PubMed ID: 10673327
[TBL] [Abstract][Full Text] [Related]
25. Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery.
Lapchak PA; Miller PJ; Collins F; Jiao S
Neuroscience; 1997 May; 78(1):61-72. PubMed ID: 9135089
[TBL] [Abstract][Full Text] [Related]
26. Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo.
Sullivan AM; Opacka-Juffry J; Blunt SB
Eur J Neurosci; 1998 Jan; 10(1):57-63. PubMed ID: 9753113
[TBL] [Abstract][Full Text] [Related]
27. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease.
Wang L; Muramatsu S; Lu Y; Ikeguchi K; Fujimoto K; Okada T; Mizukami H; Hanazono Y; Kume A; Urano F; Ichinose H; Nagatsu T; Nakano I; Ozawa K
Gene Ther; 2002 Mar; 9(6):381-9. PubMed ID: 11960314
[TBL] [Abstract][Full Text] [Related]
28. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease.
Rosenblad C; Martinez-Serrano A; Björklund A
Neuroscience; 1998 Jan; 82(1):129-37. PubMed ID: 9483509
[TBL] [Abstract][Full Text] [Related]
29. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo.
Kearns CM; Gash DM
Brain Res; 1995 Feb; 672(1-2):104-11. PubMed ID: 7749731
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease.
Sun M; Kong L; Wang X; Lu XG; Gao Q; Geller AI
Brain Res; 2005 Aug; 1052(2):119-29. PubMed ID: 16018990
[TBL] [Abstract][Full Text] [Related]
31. Glial cell line-derived neurotrophic factor prevents death, but not reductions in tyrosine hydroxylase, of injured nigrostriatal neurons in adult rats.
Lu X; Hagg T
J Comp Neurol; 1997 Nov; 388(3):484-94. PubMed ID: 9368855
[TBL] [Abstract][Full Text] [Related]
32. rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease.
Manfredsson FP; Burger C; Sullivan LF; Muzyczka N; Lewin AS; Mandel RJ
Exp Neurol; 2007 Oct; 207(2):289-301. PubMed ID: 17678648
[TBL] [Abstract][Full Text] [Related]
33. Neuroprotective effects of GDNF against 6-OHDA in young and aged rats.
Fox CM; Gash DM; Smoot MK; Cass WA
Brain Res; 2001 Mar; 896(1-2):56-63. PubMed ID: 11277973
[TBL] [Abstract][Full Text] [Related]
34. Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease.
Brizard M; Carcenac C; Bemelmans AP; Feuerstein C; Mallet J; Savasta M
Neurobiol Dis; 2006 Jan; 21(1):90-101. PubMed ID: 16084732
[TBL] [Abstract][Full Text] [Related]
35. Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system.
Rosenblad C; Georgievska B; Kirik D
Eur J Neurosci; 2003 Jan; 17(2):260-70. PubMed ID: 12542662
[TBL] [Abstract][Full Text] [Related]
36. GFR-α1 Expression in Substantia Nigra Increases Bilaterally Following Unilateral Striatal GDNF in Aged Rats and Attenuates Nigral Tyrosine Hydroxylase Loss Following 6-OHDA Nigrostriatal Lesion.
Kasanga EA; Owens CL; Cantu MA; Richard AD; Davis RW; McDivitt LM; Blancher B; Pruett BS; Tan C; Gajewski A; Manfredsson FP; Nejtek VA; Salvatore MF
ACS Chem Neurosci; 2019 Oct; 10(10):4237-4249. PubMed ID: 31538765
[TBL] [Abstract][Full Text] [Related]
37. Single or continuous injection of glial cell line-derived neurotrophic factor in the striatum induces recovery of the nigrostriatal dopaminergic system.
Aoi M; Date I; Tomita S; Ohmoto T
Neurol Res; 2000 Dec; 22(8):832-6. PubMed ID: 11149247
[TBL] [Abstract][Full Text] [Related]
38. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease.
Kirik D; Georgievska B; Rosenblad C; Björklund A
Eur J Neurosci; 2001 Apr; 13(8):1589-99. PubMed ID: 11328352
[TBL] [Abstract][Full Text] [Related]
39. Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production.
Sajadi A; Bauer M; Thöny B; Aebischer P
J Neurochem; 2005 Jun; 93(6):1482-6. PubMed ID: 15935064
[TBL] [Abstract][Full Text] [Related]
40. Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.
Yue X; Hariri DJ; Caballero B; Zhang S; Bartlett MJ; Kaut O; Mount DW; Wüllner U; Sherman SJ; Falk T
Neuroscience; 2014 Jan; 258():385-400. PubMed ID: 24291725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
